The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: Paclitaxel, ifosfamide, carboplatin, etoposide): Efficacy and safety of a triple antiemetic combination

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 784-789

  Jordan, K ^a   Jahn, F ^a   Jahn, P ^a   Behlendorf, T ^a   Stein, A ^a   Ruessel, J ^a   Kegel, T ^a   Schmoll, H J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

aprepitant; chemotherapy induced nausea and vomiting; high dose chemotherapy; NK 1 receptor antagonist; risk factors

Indexed keywords

APREPITANT; CARBOPLATIN; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; IFOSFAMIDE; MELPHALAN; PACLITAXEL;

ADULT; AGED; ANOREXIA; ANTIEMETIC ACTIVITY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HICCUP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SARCOMA; TESTIS CANCER; THROMBOCYTOPENIA; THYMUS CANCER; TREATMENT DURATION;

ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG COMBINATIONS; DRUG TOXICITY; ETOPOSIDE; FEMALE; GRANISETRON; HUMANS; IFOSFAMIDE; MALE; MELPHALAN; MIDDLE AGED; MORPHOLINES; NAUSEA; PACLITAXEL; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 79958146802     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.205     Document Type: Article

References (25)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM et al. On the receiving end - patient perception of the sideeffects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208. (Pubitemid 13155858)
2. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189-195.
3. Einhorn LH, Rapoport B, Koeller J, Grunberg SM, Feyer P, Rittenberg C et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005; 13: 112-116. (Pubitemid 40558167)
4. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947. (Pubitemid 46630595)
5. Roila F, Herrstedt J, Aapro M. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl 5): v232-v243.
6. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transplant 2008; 42: 501-506.
7. Bubalo JS, Leis JF, Curtin PT, Maziarz RT, Kovascovics TJ, Meyers G A randomized, double blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007; 25 (no. 18 s): 9112.
8. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16: 45-51.
9. Roila F, Del Favero A, Gralla R. Prevention of chemotherapy and radiotherapy-induced emesis: results of the Perugia consensus conference. Ann Oncol 1998; 9: 811-819. (Pubitemid 28440438)
10. Viner CV, Selby PJ, Zulian GB, Gore ME, Butcher ME, Wootton CM et al. Ondansetron - a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol 1990; 25: 449-453. (Pubitemid 20069346)
11. Barbounis V, Koumakis G, Hatzichristou H, Vassilomanolakis M, Tsoussis S, Efremidis A. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with highdose chemotherapy and stem cell transplantation. Support Care Cancer 1999; 7: 79-83. (Pubitemid 29140740)
12. Or R, Drakos P, Nagler A, Naparstek E, Kapelushnik J, Cass Y. The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation. Support Care Cancer 1994; 2: 245-248.
13. Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J et al. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 1997; 20: 473-478. (Pubitemid 27434895)
14. Lopez-Jimenez J, Martin-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, del Campo R et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006; 91: 84-91. (Pubitemid 43235390)
15. Climent MA, Palau J, Ruiz A, Soriano V, Aznar E, Olmos T et al. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. Support Care Cancer 1998; 6: 287-290. (Pubitemid 28213067)
16. Bubalo J, Seelig F, Karbowicz S, Maziarz RT. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 439-445. (Pubitemid 32952317)
17. Junagadhwalla MCJ, Gentile T. Prolonged administration of aprepitant does not increase toxicity in patients undergoing high dose chemotherapy and autologous stem cell transplant. Blood 2005; 106: (517b).
18. Barnet CMOM, Popat U. Evaluation of aprepitant for treatment of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing autologous stem cell transplantation. Blood 2004; 104: (343b).
19. Szer JGA, Grigg AP, Roberts AP, Raunow H. Aprepitant in the prevention of acute and delayed nausea and vomiting following haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2006; 37(Suppl I): 112.
20. Stiff P, Fox-Geimann MP, Kiley K, Fletcher-Gonzalez D, Porter N, Rychlik K et al. A prospective, randomized phase III trial of oral ondansetron and dexamethasone alone vs oral ondansetron, dexamethasone and the NK-1 Inhibitor, Aprepitant (Emend) for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. ASH 2009; 22: 2267.
21. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45: 1184-1187.
22. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119. (Pubitemid 46606178)
23. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MAG, Eldridge K, Hipple A et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebocontrolled trial in Latin America. Cancer 2003; 97: 3090-3098.
24. Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007; 18: 808-809. (Pubitemid 46523293)
25. Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14: 157-162.